The estimated Net Worth of Phillip B. Donenberg is at least $305 Tysiąc dollars as of 16 August 2023. Mr. Donenberg owns over 111,111 units of AvroBio Inc stock worth over $159,755 and over the last 7 years he sold AVRO stock worth over $0. In addition, he makes $145,053 as Independent Director at AvroBio Inc.
Phillip has made over 3 trades of the AvroBio Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 111,111 units of AVRO stock worth $100,000 on 16 August 2023.
The largest trade he's ever made was buying 111,111 units of AvroBio Inc stock on 16 August 2023 worth over $100,000. On average, Phillip trades about 6,451 units every 51 days since 2017. As of 16 August 2023 he still owns at least 114,111 units of AvroBio Inc stock.
You can see the complete history of Mr. Donenberg stock trades at the bottom of the page.
Phillip B. Donenberg CPA serves as Independent Director of the Company. Mr. Donenberg is senior vice president and chief financial officer of Project Jaguar LLC, an early-stage gene therapy company, and has served in such role since February 2020. From July 2018 to November 2018, Mr. Donenberg served as the chief financial officer and senior vice president of Assertio Therapeutics, Inc. (Nasdaq: ASRT), a pharmaceutical company. Previously, Mr. Donenberg served at AveXis, Inc. (now a Novartis company), a gene therapy company, as the senior vice president and chief financial officer from October 2017 to June 2018 and as vice president, corporate controller of AveXis, Inc. from September 2016 to October 2017. He was the chief financial officer of RestorGenex Corporation from May 2014 to January 2016, when RestorGenex merged with Diffusion Pharmaceuticals LLC, a pharmaceutical company, and served as the merged company’s consultant chief financial officer until September 2016, and the chief financial officer of 7wire Ventures LLC, an early stage healthcare venture fund, from September 2013 to May 2014. Prior to that time, Mr. Donenberg served as the chief financial officer of BioSante Pharmaceuticals, Inc. from July 1998 to June 2013, when BioSante merged with ANIP Pharmaceuticals, Inc. Mr. Donenberg also has experience serving on the boards of directors of privately held companies.
As the Independent Director of AvroBio Inc, the total compensation of Phillip Donenberg at AvroBio Inc is $145,053. There are 11 executives at AvroBio Inc getting paid more, with Birgitte Volck having the highest compensation of $4,384,270.
Phillip Donenberg is 59, he's been the Independent Director of AvroBio Inc since 2018. There are 6 older and 11 younger executives at AvroBio Inc. The oldest executive at AvroBio Inc is Christopher Paige, 67, who is the Independent Director.
Phillip's mailing address filed with the SEC is C/O TAYSHA GENE THERAPIES, INC., 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247.
Over the last 6 years, insiders at AvroBio Inc have traded over $3,066,308 worth of AvroBio Inc stock and bought 2,395,057 units worth $31,037,133 . The most active insiders traders include Braden Michael Leonard, Bruce Booth oraz Venture Fund X, L.P.Atlas V.... On average, AvroBio Inc executives and independent directors trade stock every 102 days with the average trade being worth of $206,675. The most recent stock trade was executed by Braden Michael Leonard on 13 May 2024, trading 766,635 units of AVRO stock currently worth $973,626.
clinical stage company focused on delivering step-change cell & gene therapies targeting cancer and rare disease.
AvroBio Inc executives and other stock owners filed with the SEC include: